WO2004016649A3 - Verfahren zur herstellung eines künstlichen polypeptids und nach diesem verfahren hergestelltes künstliches protein - Google Patents

Verfahren zur herstellung eines künstlichen polypeptids und nach diesem verfahren hergestelltes künstliches protein Download PDF

Info

Publication number
WO2004016649A3
WO2004016649A3 PCT/DE2003/002437 DE0302437W WO2004016649A3 WO 2004016649 A3 WO2004016649 A3 WO 2004016649A3 DE 0302437 W DE0302437 W DE 0302437W WO 2004016649 A3 WO2004016649 A3 WO 2004016649A3
Authority
WO
WIPO (PCT)
Prior art keywords
artificial
polypeptide
nucleic acid
production
function
Prior art date
Application number
PCT/DE2003/002437
Other languages
English (en)
French (fr)
Other versions
WO2004016649A2 (de
Inventor
Ludger Altrogge
Gudula Riemen
Helmut Brosterhus
Gregor Siebenkotten
Original Assignee
Amaxa Gmbh
Ludger Altrogge
Gudula Riemen
Helmut Brosterhus
Gregor Siebenkotten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amaxa Gmbh, Ludger Altrogge, Gudula Riemen, Helmut Brosterhus, Gregor Siebenkotten filed Critical Amaxa Gmbh
Priority to AU2003254630A priority Critical patent/AU2003254630A1/en
Publication of WO2004016649A2 publication Critical patent/WO2004016649A2/de
Publication of WO2004016649A3 publication Critical patent/WO2004016649A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines künstlichen Polypeptids mit mindestens einer nachweisbaren Funktion, sowie ein nach diesem Verfahren hergestelltes künstliches Protein mit mindestens einer nachweisbaren Funktion. Bei dem erfindungsgemässen Verfahren werden die Aminosäuresequenzen von zumindest drei bekannten Polypeptiden zunächst auf eine Weise nebeneinander angeordnet, dass sich gegebenenfalls unter Einführung von Lücken eine, vorzugsweise höchstmögliche, Übereinstimmung von invarianten Aminosäuren oder ähnlichen Bereichen für alle Polypeptide ergibt. Mit Hilfe dieses Abgleichs der jeweiligen Positionen der ausgewählten Aminosäuresequenzen wird eine Durchschnitts-Sequenz ermittelt. Zur Expression des Polypeptids und zum Nachweis der gewünschten Funktion wird zunächst eine künstliche Nukleinsäure­ Sequenz, die für die ermittelte Durchschnitts-Sequenz kodiert, erstellt und zumindest ein entsprechendes Nukleinsäure-Moleküls synthetisiert. Dieses Nukleinsäure-Moleküls wird mit einem geeigneten Promotor verbunden und das Polypeptid dann in einem geeigneten System exprimiert. Das erfindungsgemässe Verfahren führt also zu einem neuen, vollständig funktionsfähigen Polypeptid bzw. Protein, das die gewünschte Eigenschaft aufweist.
PCT/DE2003/002437 2002-07-19 2003-07-19 Verfahren zur herstellung eines künstlichen polypeptids und nach diesem verfahren hergestelltes künstliches protein WO2004016649A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003254630A AU2003254630A1 (en) 2002-07-19 2003-07-19 Method for the production of an artificial polypeptide and artificial proteins produced by said method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233047.6 2002-07-19
DE2002133047 DE10233047A1 (de) 2002-07-19 2002-07-19 Verfahren zur Herstellung eines künstlichen Polypeptids und nach diesem Verfahren hergestelltes künstliches Protein

Publications (2)

Publication Number Publication Date
WO2004016649A2 WO2004016649A2 (de) 2004-02-26
WO2004016649A3 true WO2004016649A3 (de) 2004-04-22

Family

ID=30774928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/002437 WO2004016649A2 (de) 2002-07-19 2003-07-19 Verfahren zur herstellung eines künstlichen polypeptids und nach diesem verfahren hergestelltes künstliches protein

Country Status (3)

Country Link
AU (1) AU2003254630A1 (de)
DE (1) DE10233047A1 (de)
WO (1) WO2004016649A2 (de)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1998047089A1 (en) * 1997-04-11 1998-10-22 California Institute Of Technology Apparatus and method for automated protein design
EP0897985A2 (de) * 1997-07-24 1999-02-24 F.Hoffmann-La Roche Ag Konsensus-Phytasen
WO2000023564A2 (en) * 1998-10-16 2000-04-27 Xencor, Inc. Protein design automation for protein libraries
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
WO2001034824A2 (en) * 1999-11-10 2001-05-17 Rigel Pharmaceuticals, Inc. Methods and compositions comprising renilla gfp
WO2001059066A2 (en) * 2000-02-10 2001-08-16 Xencor, Inc. Protein design automation for protein libraries
WO2002005146A2 (en) * 2000-07-10 2002-01-17 Xencor, Inc. Method for disigning protein libraries with altered immunogenicity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1998047089A1 (en) * 1997-04-11 1998-10-22 California Institute Of Technology Apparatus and method for automated protein design
EP0897985A2 (de) * 1997-07-24 1999-02-24 F.Hoffmann-La Roche Ag Konsensus-Phytasen
WO2000023564A2 (en) * 1998-10-16 2000-04-27 Xencor, Inc. Protein design automation for protein libraries
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
WO2001034824A2 (en) * 1999-11-10 2001-05-17 Rigel Pharmaceuticals, Inc. Methods and compositions comprising renilla gfp
WO2001059066A2 (en) * 2000-02-10 2001-08-16 Xencor, Inc. Protein design automation for protein libraries
WO2002005146A2 (en) * 2000-07-10 2002-01-17 Xencor, Inc. Method for disigning protein libraries with altered immunogenicity

Also Published As

Publication number Publication date
DE10233047A1 (de) 2004-02-26
AU2003254630A8 (en) 2004-03-03
AU2003254630A1 (en) 2004-03-03
WO2004016649A2 (de) 2004-02-26

Similar Documents

Publication Publication Date Title
WO2004101759A3 (en) Novel lipolytic enzyme lip2
AU2002360331A1 (en) Egviii endoglucanase and nucleic acids encoding the same
WO2004101760A3 (en) Novel lipolytic enzyme elip
ATE310090T1 (de) Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren
WO2003052055A3 (en) Egvii endoglucanase and nucleic acids encoding the same
WO2003052057A3 (en) Egvi endoglucanase and nucleic acids encoding the same
WO2000075350A3 (en) Nucleic acid sequences encoding proteins involved in fatty acid beta-oxidation and methods of use
WO2002016418A3 (en) An iap binding peptide or polypeptide and methods of using the same
WO2011010304A3 (en) Method for preparing molecularly imprinted polymers and uses thereof
DE69827810D1 (de) Methode zum durchforsten von banken mittels chimären bindungspetiden
AU1283288A (en) Production and purification of a protein fused to a binding protein
WO2004016649A3 (de) Verfahren zur herstellung eines künstlichen polypeptids und nach diesem verfahren hergestelltes künstliches protein
WO1995008628A3 (en) Nucleic acids encoding merosin, merosin fragments and uses thereof
WO2003070768A3 (en) Cd40 splice variants,method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
WO2005116658A3 (en) Method for determining a tissue degradation process by detection of comp neoepitopes
WO2000015789A1 (en) Recombinant bioadhesive protein analogs comprising hydroxyproline
WO2004065554A3 (en) Human saa3 nucleic acid molecule, protein, and methods of use for same
WO2003076569A3 (en) Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
WO2004109579A3 (en) Protein identification methods and systems
WO2024091897A3 (en) De novo designed modular peptide binding proteins by superhelical matching
WO2002081629A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2003902414A0 (en) Flowering induction
WO2002046406A3 (en) Human transporter proteins, nucleic acid molecules encoding them,and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP